Skip to content
MarketScale
‹ Back to IndustriesHealthcare

CurveBeam Connect: Harnessing the Data from Medical Imaging to Supercharge Orthopedics

Orthopedic surgeries have progressed advancements since the first robotic-assisted surgery in medicine 36 years ago. Dr. Stefano Bini, knee arthroplasty expert and academic at University of California San Francisco (UCSF), discussed these advancements with Host Vinti Singh.   The medical industry is seeing more interest in artificial intelligence (AI) to identify outcomes and risk factors….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from CurveBeam AI on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Orthopedic surgeries have progressed advancements since the first robotic-assisted surgery in medicine 36 years ago. Dr. Stefano Bini, knee arthroplasty expert and academic at University of California San Francisco (UCSF), discussed these advancements with Host Vinti Singh.

The medical industry is seeing more interest in artificial intelligence (AI) to identify outcomes and risk factors. Another trend is hospital management using technology for administrative processes such as intake, referral management and patient engagement. Additionally, robotics continues to dominate the operating room as technological variability decreases and raises the return on investment.

Of these technological advancements, orthopedics is the number two medical discipline leveraging 3D printing to visualize tissue complexity. 3D holograms are even used via phones or iPads so surgeons can manipulate the model with improved accessibility.

However, not all physicians are running to adopt these trends. Dr. Bini explained that resistance will eventually ease. “When the technology is presented in such a way that it clearly solves a pain point, and it does so at a price point and at an adoption point that is manageable for that particular person in the environment, then it tends to be adopted rather quickly,” he stated.

Data segmentation, the process of segmenting bones and other features medical images to enable advanced analysis, is also advancing.

Machine learning algorithms are becoming stronger as more data sets appear. “We’re going to move forward to an algorithmically driven segmentation that is getting better and better. I’d say you will see clinical applications over the next two to three years,” Dr. Bini said. Adoption of synthetic data, which are sets statistically equal to but different from the original set, eliminate history of present illness issues and will drive AI modelling accuracy.

For more information on these trends, subscribe to the podcast on Apple iTunes or Spotify and visit the curvebeam.com website for imaging solutions and AI insight.

Visit docsf.health for more information on the Digital Orthopaedics Conferences in San Francisco.

CurveBeam AI

Part of this channel

CurveBeam AI

AI-powered 3D bone analysis for orthopedic surgical planning.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

ChatGPT for Healthcare can now read from Epic. UCSF Health is piloting the read-only integration, according to Fierce Healthcare and Becker’s Hospital Review. For CIOs, the work is permissions, auditability, and clinical validation in Epic workflows.

  • 01The “read-only” label doesn’t remove governance work, it moves it to permissions mapping, audit logs, and connector scope design inside Epic-supported workflows.
  • 02OpenAI’s published clinician review results (99.1% rated safe across 4,363 ratings) are a useful benchmark, but they still need local validation on your own note templates, meds workflows, and specialty mix.

Sep 7, 2026

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512